Abstract: The present invention relates to an ophthalmic aqueous composition containing PGF2? analogues for treating ocular hypertension and glaucoma, to a method for treating ocular hypertension and glaucoma by administering said composition to a subject in need of such treatment, and to a method for increasing aqueous solubility and stability of PGF2? analogues in an aqueous composition.

Abstract: The present invention relates to an ophthalmic aqueous composition containing PGF2? analogues for treating ocular hypertension and glaucoma, to a method for treating ocular hypertension and glaucoma by administering said composition to a subject in need of such treatment, and to a method for increasing aqueous solubility and stability of PGF2? analogues in an aqueous composition.

Abstract: The present invention relates to an ophthalmic aqueous composition containing PGF2? analogues for treating ocular hypertension and glaucoma, to a method for treating ocular hypertension and glaucoma by administering said composition to a subject in need of such treatment, and to a method for increasing aqueous solubility and stability of PGF2? analogues in an aqueous composition.

Abstract: The present invention relates to an ophthalmic aqueous composition containing PGF2? analogs for treating ocular hypertension and glaucoma, to a method for treating ocular hypertension and glaucoma by administering said composition to a subject in need of such treatment, and to a method for increasing aqueous solubility and stability of PGF2? analogs in an aqueous composition.

Abstract: The present invention relates to a method for improving ocular bioavailability of latanoprost by adding an organic amine to an aqueous eye drop composition containing latanoprost. The invention further relates to an aqueous eye drop composition in which a better ocular bioavailability of latanoprost is achieved by adding an organic amine, and to a method for treating occular hypertension and glaucoma by administering said composition to a subject in need of such treatment.

Abstract: The present invention relates to an ophthalmic aqueous composition containing PGF2? analogues for treating ocular hypertension and glaucoma, to a method for treating ocular hypertension and glaucoma by administering said composition to a subject in need of such treatment, and to a method for increasing aqueous solubility and stability of PGF2? analogues in an aqueous composition.

Abstract: A surgical implant made of a polymer, copolymer, polymer mixture or polymer composite that dissolves in the organ system. The manufacturing material is dyed with the coloring agent D&C Violet No. 2 or D&C Green No. 6. Preferably, the amount of the coloring agent is at most approximately 0.03 percent by weight and the implant is sterilized by radiation.

Abstract: An instrument for shaping a mouth part of a drilled tunnel provided in a bone. The instrument includes a shaft having a longitudinal axis and a first and a second end. The first end of the shaft is provided with a projection, which includes a blade for shaping the mouth part of the drilled tunnel when the instrument is turned around the longitudinal axis of the shaft. The instrument is asymmetric at an intersecting surface perpendicular to the longitudinal axis and intersecting with the blade, the instrument thus shaping the surfaces surrounding the first end only substantially within an area corresponding with a turning angle of such a turning movement.

Abstract: An instrument for shaping a mouth part of a drilled tunnel provided in a bone. The instrument includes a shaft having a longitudinal axis and a first and a second end. The first end of the shaft is provided with a projection, which includes a blade for shaping the mouth part of the drilled tunnel when the instrument is turned around the longitudinal axis of the shaft. The instrument is asymmetric at an intersecting surface perpendicular to the longitudinal axis and intersecting with the blade, the instrument thus shaping the surfaces surrounding the first end only substantially within an area corresponding with a turning angle of such a turning movement.

Abstract: A surgical implant made of a polymer, copolymer, polymer mixture or polymer composite that dissolves in the organ system. The manufacturing material is dyed with the coloring agent D&C Violet No. 2 or D&C Green No. 6. Preferably, the amount of the coloring agent is at most approximately 0.03 percent by weight and the implant is sterilized by radiation.

Abstract: The present invention is directed to an ophthalmic composition in the form of a topical aqueous solution consisting essentially ofan ophthalmologically active agent containing basic groups,an ion sensitive, hydrophilic polymer containing acidic groups in an amount of 0.004 to 1.5% by weight,at least one salt selected from the group of inorganic salts and buffers in a total amount of from 0.01 to 2.0% by weight,and optionally a wetting agent and a preservative, the ratio between salt and polymer being such that the solution exhibits a viscosity of less than 1000 mpas, and the pH of the solution is 4.0 to 8.0. The composition contains a sufficient amount of polymer to provide for a controlled absorption of the drug into the eye, its viscosity having been reduced to provide for better handling characteristics.

Abstract: The present invention relates to an eye drop formulation, which, in combination, comprises a single polymer, pilocarpine, a beta-blocking agent and an ophthalmologically acceptable carrier wherein the pH of the formulation is from 3.5 to 5.8 and the viscosity is from 10 to 25000 mPas.

Abstract: The present invention is directed to an ophthalmic composition in the form of a topical aqueous solution consisting essentially ofan ophthalmologically active agent,an ion sensitive, hydrophilic polymer in an amount a of 0.004 to 1.5% by weight,at least one salt selected from the group of inor ganic salts and buffers in a total amount of from 0.01 to 2.0% by weight,a wetting agent in an amount of 0 to 3.0% by weight,a preservative in an amount of 0 to 0.02% by weight,water, and optionallya pH regulating agent in an amount sufficient to give a pH of 4.0 to 8.0 to the composition,the ratio between salt and polymer components being such that the solution exhibits a viscosity of less than 1000 mPas. The composition contains a sufficient amount of polymer to provide for a controlled absorption of the drug into the eye, its viscosity having been reduced to provide for better handling characteristics.